2024
Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
Allen P, Bagley E, Graf K, Sethi T, Foss F, Dong N, Saeed H, Wang J, Dittus C, Paulino D, Wilcox R, Barta S, Carvajal V, Mehta-Shah N, Mou E, Ravindra A, Haverkos B, Mehta A, Shea L, Zain J, Reef D, Ayzman A, Greenwell I. Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study. Blood 2024, 144: 1690. DOI: 10.1182/blood-2024-211424.Peer-Reviewed Original ResearchExtranodal NK/T-cell lymphomaNK/T-cell lymphomaAsparaginase useENKTL patientsResponse rateTreatment patternsDiscontinued due to toxicityMulticenter retrospective cohort studyNon-ASP groupAssociated with significant ratesTherapy related deathsEBV-associated lymphomasKaplan-Meier methodCox proportional hazards regressionRetrospective cohort studyQuarter of patientsProportional hazards regressionStatistically significant advantageHigh response rateLimitations of therapyAnalysis of outcomesAssociated lymphomaChemotherapy backboneNeutropenic feverAsparaginase dosesDevelopment of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
Koh M, Han J, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Kim J, Kim Y, Cho J, Eipe T, Shet T, Sridhar E, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al Mansour M, Ford J, Manni M, Civallero M, Skrypets T, Federico M, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium. Blood 2024, 144: 465. DOI: 10.1182/blood-2024-201874.Peer-Reviewed Original ResearchNK-cell lymphomasMature T cellsMultivariate Cox regressionCytotoxic chemotherapyOverall survivalNK cellsT cellsAssociated with inferior OSPeripheral T-cell lymphomaInternational retrospective cohort studySecond-line treatmentT-cell lymphomaRetrospective cohort studyIdentification of risk factorsR/R patientsInferior OSPrognostic factorsPrognostic scorePrognostic valueTreatment detailsHighest concordance indexUnivariate analysisDiagnosed patientsConcordance indexC-indexGlobal outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium
Han J, Koh M, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Fernandez Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al-Mansour M, Ford J, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium. Blood Advances 2024 PMID: 39481087, DOI: 10.1182/bloodadvances.2024014674.Peer-Reviewed Original ResearchNK-cell lymphomasOverall survivalMature T cellsALK-ALCLNK cellsT cellsAssociated with 3-year OSTiming of second-line treatmentSuperior median overall survivalMedian overall survivalPrimary refractory diseaseProgression-free survivalInternational retrospective cohort studySecond-line treatmentEfficacy of novel drugsIdentified several independent predictorsRetrospective cohort studyR/R lymphomaExtranodal sitesPTCL-NOSIntermediate-riskCytotoxic chemotherapyHistological subtypesRefractory diseaseRelapsed lymphoma
2023
Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study
Sorial M, Koh M, Boussi L, Han J, Peng L, Eche-Ugwu I, Duan R, Lei M, Miranda E, Chiattone C, Stuver R, Horwitz S, Turizo M, McCabe S, Merrill M, Jacobsen E, Kim J, Kim Y, Cho J, Jain H, Sengar M, Eipe T, Shet T, Singh S, Lou U, Raghib H, Gabler J, Koh M, Van Der Weyden C, Prince M, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al Mansour M, Ford J, Manni M, Federico M, O'Connor O, Cabrera M, Marchi E, Shen C, Shah D, Jain S. Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study. Blood 2023, 142: 3080. DOI: 10.1182/blood-2023-182341.Peer-Reviewed Original ResearchNK-cell neoplasmsTherapy sequenceCohort studyMost patientsSurvival outcomesPatient cohortCox modelAnaplastic large cell lymphomaFirst lineAllogeneic hematopoietic transplantOptimal therapy sequencePTCL-NOS patientsRetrospective cohort studyKaplan-Meier curvesLarge cell lymphomaEpigenetic modifiersImmunomodulatory imide drugsPI3K inhibitorsAntibody-drug conjugatesAllogeneic HSCTCommon histologyPlanned subgroupPrimary refractoryAutologous HSCTHazard ratio